/wp-content/uploads/logo.png00eallison/wp-content/uploads/logo.pngeallison2022-05-25 09:43:382022-05-25 09:58:16Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
/wp-content/uploads/logo.png00David Anderson/wp-content/uploads/logo.pngDavid Anderson2022-02-07 05:05:122022-02-10 08:50:07Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/wp-content/uploads/logo.png00Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 14:48:512022-02-03 18:59:03Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
/wp-content/uploads/logo.png00Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 15:00:242022-02-03 19:02:50Endeavor Biomedicines Licenses Ulk1/2 Inhibitor Program From Salk Institute And Sanford Burnham Prebys To Broaden Its Precision Oncology Pipeline
/wp-content/uploads/logo.png00Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 15:01:212022-02-03 19:01:25Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
https://endeavorbiomedicines.com/wp-content/uploads/scrip-logo-1.svg52169Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-19 15:50:002022-01-19 15:50:00Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
https://endeavorbiomedicines.com/wp-content/uploads/Stat_News_logo-gray.svg100100Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-21 17:34:072022-01-21 17:47:16Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
https://endeavorbiomedicines.com/wp-content/uploads/linkedin-gray.svg100100Emily Hennes/wp-content/uploads/logo.pngEmily Hennes2022-01-31 18:09:392022-02-01 18:52:55My newest puzzle, Endeavor BioMedicines, and the chance to reverse a devastating pulmonary disease
Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
/in news, Press ReleaseMay 25, 2022
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/in news, Press ReleaseFebruary 07, 2022
Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
/in news, Press ReleaseSeptember 22, 2021
Endeavor Biomedicines Licenses Ulk1/2 Inhibitor Program From Salk Institute And Sanford Burnham Prebys To Broaden Its Precision Oncology Pipeline
/in news, Press ReleaseSeptember 16, 2021
Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
/in news, Press ReleaseJanuary 7, 2021